Literature DB >> 30932994

INVOLUTION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AFTER ENDOPHTHALMITIS.

Gregg T Kokame1,2,3,4,5, Nicolas A Yannuzzi6, Jessica G Shantha2,3,4,7, Maya Yamane8, Nidhi Relhan6, Jeffrey Gross9, Edwin H Ryan10, Harry W Flynn6.   

Abstract

PURPOSE: To report patients who demonstrated an alteration in the clinical and optical coherence tomography features of neovascular age-related macular degeneration after resolution of endophthalmitis.
METHODS: Retrospective case series of the subsequent changes in the macula and need for anti-vascular endothelial growth factor therapy in patients with neovascular age-related macular degeneration who developed endophthalmitis after intravitreal injection.
RESULTS: The study included seven eyes of seven patients with follow-up ranging between 3 months and 11 years. The vitreous cultures (n = 7) before intravitreal antibiotic injection were the following: culture-negative (4) and coagulase-negative Staphylococcus (3). Initial treatment included vitreous tap and injection (4) and pars plana vitrectomy (3). In 5/7 eyes, the optical coherence tomography showed resolution of subretinal fluid and serous pigment epithelial detachment, and there was no additional anti-vascular endothelial growth factor treatment administered.
CONCLUSION: After successful treatment of endophthalmitis in patients with neovascular age-related macular degeneration, there was relative involution of the maculopathy and reduced anti-vascular endothelial growth factor treatment burden in this series.

Entities:  

Mesh:

Year:  2021        PMID: 30932994      PMCID: PMC6765457          DOI: 10.1097/ICB.0000000000000866

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  15 in total

1.  Intravitreal bevacizumab and ranibizumab for choroidal neovascularization secondary to endogenous endophthalmitis.

Authors:  Alice M Fecko; Lawrence Y Ho; Mark K Walsh; George A Williams
Journal:  Retin Cases Brief Rep       Date:  2011

2.  Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.

Authors:  Andrew A Moshfeghi; Philip J Rosenfeld; Harry W Flynn; Stephen G Schwartz; Janet L Davis; Timothy G Murray; William E Smiddy; Audina M Berrocal; Sander R Dubovy; Wen-Hsiang Lee; Thomas A Albini; Geeta A Lalwani; Jaclyn L Kovach; Carmen A Puliafito
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

3.  Photodynamic therapy outcomes in a case of macular choroidal neovascularization secondary to Candida endophthalmitis.

Authors:  M Tedeschi; M Varano; D Schiano Lomoriello; C Scassa; V Parisi
Journal:  Eur J Ophthalmol       Date:  2007 Jan-Feb       Impact factor: 2.597

4.  Choroidal neovascularaization secondary to Klebsiella pneumoniae endogenous abscess and endophthalmitis.

Authors:  Angie H C Fong; Kenneth K W Li; Hayden C K Jon; Wico W K Lai; David Wong
Journal:  Clin Exp Ophthalmol       Date:  2009-03       Impact factor: 4.207

Review 5.  Ocular oxygenation and the treatment of diabetic retinopathy.

Authors:  Einar Stefánsson
Journal:  Surv Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 6.048

6.  Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.

Authors:  Ninel Z Gregori; Harry W Flynn; Stephen G Schwartz; Philip J Rosenfeld; Kamyar Vaziri; Andrew A Moshfeghi; Jorge A Fortun; Jaclyn L Kovach; Sander R Dubovy; Thomas A Albini; Janet L Davis; Audina M Berrocal; William E Smiddy
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-06       Impact factor: 1.300

7.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

8.  Anatomic and visual outcomes of noninfectious endophthalmitis after intravitreal triamcinolone.

Authors:  Steven J Yoon; David Y Rhee; Jeffrey L Marx; Gregory R Blaha; Adam H Rogers; Caroline R Baumal; Elias Reichel; Jay S Duker
Journal:  Am J Ophthalmol       Date:  2009-03-09       Impact factor: 5.258

9.  Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.

Authors:  Rufino Silva; András Berta; Michael Larsen; Wayne Macfadden; Chrystel Feller; Jordi Monés
Journal:  Ophthalmology       Date:  2017-10-12       Impact factor: 12.079

10.  Role of guanylate binding protein-1 in vascular defects associated with chronic inflammatory diseases.

Authors:  Matthias Hammon; Martin Herrmann; Oliver Bleiziffer; Galyna Pryymachuk; Laura Andreoli; Luis E Munoz; Kerstin U Amann; Michele Mondini; Marisa Gariglio; Paolo Airó; Vera S Schellerer; Antonis K Hatzopoulos; Raymund E Horch; Ulrich Kneser; Michael Stürzl; Elisabeth Naschberger
Journal:  J Cell Mol Med       Date:  2011-07       Impact factor: 5.310

View more
  1 in total

Review 1.  Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review.

Authors:  Rupali Singh; Samaneh Davoudi; Steven Ness
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-12       Impact factor: 3.535

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.